Biofrontera announces preliminary revenue for Q1 2021
Biofrontera AG reported preliminary first-quarter 2021 revenues of approximately EUR 5.6 million, a 14% decline from EUR 6.5 million in Q1 2020. US product sales dropped to EUR 3.9 million (down 6%), while Germany showed improvement with EUR 1.4 million (up 7%). However, sales in the rest of Europe fell to EUR 0.3 million, marking a decline of 69%. Notably, March 2021 sales in the USA surged 46% year-on-year, reflecting recovery likely due to high vaccination rates.
- March 2021 US sales increased by approximately 46% year-on-year, indicating recovery.
- Revenue from product sales in Germany grew by 7% year-on-year.
- Overall revenue declined by 14% compared to Q1 2020.
- US product sales decreased by 6% year-on-year.
- Sales in the rest of Europe fell significantly by 69%.
Leverkusen, Germany, April 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the first quarter 2021.
The Company’s preliminary unaudited revenue for the period January 1 to March 31, 2021 amounts to approximately EUR 5.6 million compared to EUR 6.5 million in the same period last year, a decline of
Preliminary revenues from product sales in the US were around EUR 3.9 million, compared to EUR 4.2 million in Q1 2020, which corresponds to a decline of
While sales in Germany remained relatively stable over the quarter compared to the previous year, revenues in the USA for the months of January and February 2021 were well below those of the previous year due to the pandemic. Starting in the second half of March last year, our sales were significantly impacted by the pandemic, and this is where we already saw a significant upturn this year in the USA compared to last year. In March 2021, our sales in the USA increased by around
-End-
Biofrontera AG
Pamela Keck, Head of Investor Relations
ir@biofrontera.com
+49-214-87632-0
About Biofrontera:
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.
The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi® for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.
Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ. www.biofrontera.com.
FAQ
What were Biofrontera's preliminary revenues for Q1 2021?
How did Biofrontera's US sales perform in Q1 2021?
What was the percentage decline in Biofrontera's overall revenue year-on-year?
Did Biofrontera experience any revenue growth in Germany?
How did Biofrontera's sales in the rest of Europe change in Q1 2021?
